Neurodegeneration News and Research

RSS

Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons.

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.

12 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia. However, a study in the October Journal of Lipid Research finds that similar statin drugs can have profoundly different effects on brain cells -both beneficial and detrimental.

29 Oct 2009

HBO treatments may improve neurological outcome after traumatic brain injury

Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced that researchers in its Slavica BioChem division have reported new positive results of experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored.

22 Oct 2009

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

A team of researchers from Michigan State University and the University of Cincinnati have been awarded a $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant.

15 Oct 2009

Burnham Institute officially dedicates its new research facility at Lake Nona

Today, Burnham Institute for Medical Research (Burnham) officially dedicated its new 175,000-square-foot scientific facility and marked the opening of Orlando’s Medical City as a life science center. Burnham at Lake Nona is the research anchor for the new development in southeast Orange County and the east coast campus of the La Jolla, Calif.-based institute.

9 Oct 2009

Laureate Pharma sign development and manufacturing agreement with ZZ Biotech

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a development and manufacturing agreement with ZZ Biotech, LLC. According to the agreement, Laureate will produce Activated Protein C variant under cGMP conditions. Terms of the manufacturing agreement were not disclosed.

28 Sep 2009

CICbioGUNE develops Tandem-repeated Ubiquitin Binding Entities for purifying ubiquitylated proteins

LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed by Dr. Manuel S. Rodriguez of the proteomics unit of the CICbioGUNE in Spain, will be launched in October 2009.

24 Sep 2009

Novel cleavage sites for enzyme caspase-3 identified

Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.

22 Sep 2009

Research program to study personalized medicine

A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.

18 Sep 2009

Research reveals that reactive oxygen inhibition can limit cancer cell invasion

Researchers at the Burnham Institute for Medical Research (Burnham) have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis.

17 Sep 2009

DNage's observational study assesses natural progression of CS in children

Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).

17 Sep 2009

New book on human genetics helps to unravel complex human diseases

Many human diseases-including Alzheimer's disease, schizophrenia, cancer, and cardiovascular disease-are caused by multiple genetic variants and the interaction of those variants with the environment. Because such diseases lack a clear-cut inheritance pattern, sophisticated technological approaches and statistical analyses are required to determine their underlying cause.

15 Sep 2009

Calcium stones and cell death is linked to prolonged stressful conditions

Study shows prolonged stress sparks ER to release calcium stores and induce cell death in aging-related diseases such as atherosclerosis, diabetes and neurodegeneration

15 Sep 2009

Conserved protein modulates and protects heart function against aging

Investigators at Burnham Institute for Medical Research (Burnham) have found that the conserved protein d4eBP modulates cardiac aging in Drosophila (fruit flies). The team also found that d4eBP, which binds to the protein dEif4e, protects heart function against aging.

15 Sep 2009

Major advance in understanding Friedreich's ataxia

University of Sydney researchers have made a significant advance in understanding the debilitating hereditary disease Friedreich's ataxia, offering hope that new forms of treatment will be developed.

8 Sep 2009

New target for cancer cure identified

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

3 Sep 2009

Enzymes could be targeted to kill dangerous pathogens

Researchers at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens.

28 Aug 2009